NZ331647A - Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives - Google Patents

Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives

Info

Publication number
NZ331647A
NZ331647A NZ331647A NZ33164797A NZ331647A NZ 331647 A NZ331647 A NZ 331647A NZ 331647 A NZ331647 A NZ 331647A NZ 33164797 A NZ33164797 A NZ 33164797A NZ 331647 A NZ331647 A NZ 331647A
Authority
NZ
New Zealand
Prior art keywords
nr9cor10
haloalkyl
halo
alkyl
disorder
Prior art date
Application number
NZ331647A
Inventor
Parthasarathi Rajagopalan
Robert John Chorvat
Rajagopal Bakthavatchalam
James Peter Beck
Paul Joseph Gilligan
Richard Eric Olson
Original Assignee
Du Pont Pharm Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Du Pont Pharm Co filed Critical Du Pont Pharm Co
Publication of NZ331647A publication Critical patent/NZ331647A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/34—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/52—Two oxygen atoms
    • C07D239/54—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals
    • C07D239/545—Two oxygen atoms as doubly bound oxygen atoms or as unsubstituted hydroxy radicals with other hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

A CRF antagonist of the formula 1 or II where X is N or CR1 Y is N or CR2 Z is NR3, O or S(O)n G is O or S Q is O or S(O)n n is 1or 2 Ar is phenyl, naphthyl, pyridyl, pyrimidinyl, triazinyl, furanly, quinolinyl, isoquinolinyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrrolyl, oxazolyl, benzofuranyl, benzothienyl, benzthiazolyl, isoxazolyl or pyrazolyl each optionally substituted with 1-4 R5 groups which is defined in the specification R1 is H, C1-4 alkyl, C2-4 alkenyl, C2-4 alkynyl, halo, CN, C1-4 haloalkyl, -NR9R10, NR9COR10, OR11, SH or -S(O)nR12 R2 is H, C1-4 alkyl, C1-6 cycloalkyl, halo, CN, -NR6R7, NR9COR10, C1-4 haloalkyl, -OR7, SH or -S(O)nR12. R9, R10, R6, R7, R11 and R12 are defined in the specification. Further claimed is the use of these compounds for treating affective disorder, anxiety, depression, irritable bowel syndrome, post-traumatic stress disorder, supranuclear palsy, immune suppression, Alzheimer's disease, gastrointestinal disease, anorexia and other feeding disorders, drug and alcohol withdrawal symptoms, drug addiction, inflammatory disorder or fertility problems.
NZ331647A 1996-03-26 1997-03-25 Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives NZ331647A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1409096P 1996-03-26 1996-03-26
US64661196A 1996-05-08 1996-05-08
PCT/US1997/004828 WO1997035846A1 (en) 1996-03-26 1997-03-25 Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives

Publications (1)

Publication Number Publication Date
NZ331647A true NZ331647A (en) 2000-03-27

Family

ID=26685647

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ331647A NZ331647A (en) 1996-03-26 1997-03-25 Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives

Country Status (6)

Country Link
EP (1) EP0901476A4 (en)
JP (1) JP2000507552A (en)
AU (1) AU725254B2 (en)
CA (1) CA2249598A1 (en)
NZ (1) NZ331647A (en)
WO (1) WO1997035846A1 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19653646A1 (en) * 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
BR9915129A (en) 1998-11-12 2001-08-07 Neurocrine Biosciences Inc Crf receptor antagonists and related processes
DK1129091T3 (en) 1998-11-12 2002-11-04 Neurocrine Biosciences Inc Antagonists of CRF receptors and their associated methods
US6432989B1 (en) 1999-08-27 2002-08-13 Pfizer Inc Use of CRF antagonists to treat circadian rhythm disorders
US6589952B2 (en) 2000-07-14 2003-07-08 Bristol-Myers Squibb Pharma Company Imidazo[1,2-a]pyrazines for the treatment of neurological disorders
MXPA03008185A (en) 2001-03-13 2004-01-29 Bristol Myers Squibb Pharma Co 4-(2-butylamino)-2,7-dimethyl-8-(2-methyl-6-methoxypyrid-3-yl) pyrazolo-[1,5-a]-1,3, 5-triazine, its enantiomers and pharmaceutically acceptable salts as corticotropin releasing factor receptor ligands.
CZ20033053A3 (en) 2001-05-14 2004-05-12 Bristol@Myersásquibbápharmaácompany Substituted pyrazinones, pyridines and pyrimidines as corticotropin releasing factor ligands
US6894045B2 (en) 2001-07-12 2005-05-17 Bristol-Myers Squibb Pharma Company Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands
WO2003006015A1 (en) 2001-07-13 2003-01-23 Bristol-Myers Squibb Pharma Company Substituted thiazoles and oxazoles as corticotropin releasing hormone ligands
US20030119831A1 (en) 2001-11-20 2003-06-26 Hartz Richard A. 3,7-dihydro-purine-2,6-dione derivatives as CRF receptor ligands
GB0219746D0 (en) * 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
KR20210061202A (en) * 2019-11-19 2021-05-27 일동제약(주) Benzonitrile-substituted Fused pyrimidine derivatives and their pharmaceutical use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4076711A (en) * 1976-04-05 1978-02-28 Schering Corporation Triazolo [4,5-d]-pyrimidines
JPS56131586A (en) * 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd Triazolopyrimidine derivative and its preparation
JPS56131587A (en) * 1980-03-18 1981-10-15 Ss Pharmaceut Co Ltd 7-substituted triazolopyrimidine derivative and its preparation
JPS5962595A (en) * 1982-09-30 1984-04-10 Ss Pharmaceut Co Ltd 3,5,7-trisubstituted-triazolopyrimidine derivative and its preparation
EP0141927B1 (en) * 1983-08-18 1991-10-30 Beecham Group Plc Antiviral guanine derivatives
DE3722802A1 (en) * 1987-07-10 1989-01-19 Hoechst Ag 2-AMINO-8-AZA PURINS SUBSTITUTED IN 6 AND 9 POSITIONS, THEIR USE, MEDICINAL PRODUCTS CONTAINING THESE PURINES AND METHOD FOR THE PRODUCTION OF THE PURINS
US4916224A (en) * 1988-01-20 1990-04-10 Regents Of The University Of Minnesota Dideoxycarbocyclic nucleosides
GB9011623D0 (en) * 1990-05-24 1990-07-11 Efamol Holdings Synthesis of nucleotide and nucleoside derivatives
WO1994013676A1 (en) * 1992-12-17 1994-06-23 Pfizer Inc. Pyrrolopyrimidines as crf antagonists
TW370529B (en) * 1992-12-17 1999-09-21 Pfizer Pyrazolopyrimidines
RU2153494C2 (en) * 1993-10-12 2000-07-27 Дзе Дюпон Мерк Фармасьютикал Компани 1-n-alkyl-n-arylpyrimodineamines, method of patient treatment, pharmaceutical composition
GB9400987D0 (en) * 1994-01-19 1994-03-16 Reese Colin B Production of nucleoside analogues
CA2192208C (en) * 1994-06-06 2002-09-10 Pfizer Limited Substituted pyrazoles
TW574214B (en) * 1994-06-08 2004-02-01 Pfizer Corticotropin releasing factor antagonists
ATE182332T1 (en) * 1994-06-16 1999-08-15 Pfizer PYRAZOLO AND PYRROLOPYRIDINES
DK0778277T3 (en) * 1995-12-08 2003-10-27 Pfizer Substituted heterocyclic derivatives as CRF antagonists

Also Published As

Publication number Publication date
WO1997035846A1 (en) 1997-10-02
CA2249598A1 (en) 1997-10-02
EP0901476A1 (en) 1999-03-17
AU725254B2 (en) 2000-10-12
JP2000507552A (en) 2000-06-20
EP0901476A4 (en) 2001-08-16
AU2545397A (en) 1997-10-17

Similar Documents

Publication Publication Date Title
NZ331647A (en) Aryloxy- and arylthio-fused pyridines and pyrimidines and derivatives
KR100990771B1 (en) [4-benzo[b]thiophen-2-ylpyrimidin-2-yl]-amine derivatives as ikk-beta inhibitors for the treatment of cancer and inflammatory diseases
MXPA03011324A (en) Novel benzothienyl or indole derivatives, and use thereof as inhibitors of prenyl transferase proteins.
ES2299826T3 (en) PIRIMIDIN-2-ONA COMPOUNDS AND ITS USE AS LEGANDS OF THE DOPAMINE DE3 RECEIVER.
US7229995B2 (en) Gonadotropin-releasing hormone receptor antagonists and methods relating thereto
ATE162521T1 (en) 3-AMINOPIPERIDINE DERIVATIVES AND RELATED NITROGEN CONTAINING HETEROCYCLIC COMPOUNDS
EA199800907A1 (en) DERIVATIVES OF CARBOLINE
AU2003226553A1 (en) Inhibitors of histone deacetylase
CA2428844A1 (en) Tetrahydrobenzazepine derivatives useful as modulators of dopamine d3 receptors (antipsychotic agents)
NZ331319A (en) Cyclic amine derivatives that are CCR-3 receptor (chemokine receptor) antagonists, compositions containing them and methods for their use (to combat eosinophil induced diseases).
RS50444B (en) Pyrrole substituted 2-indolinone protein kinase inhibitors
DE69232588T2 (en) Condensed tricyclic, nitrogen-containing compounds as substance P receptor antagonists
Secrist III et al. Studies directed toward a total synthesis of nucleoside Q. Annulation of 2, 6-diaminopyrimidin-4-one with. alpha.-halo carbonyls to form pyrrolo [2, 3-d] pyrimidines and furo [2, 3-d] pyrimidines
ES2130138T3 (en) XANTINA DERIVATIVE.
BR0201087A (en) Benzotriazole anti-inflammatory compounds
ES366910A1 (en) A procedure for preparing 1-glycosil-5-azacitosines. (Machine-translation by Google Translate, not legally binding)
US6958349B2 (en) Heteroaryl alkylamide derivatives useful as bradykinin receptor modulators
UA78563C2 (en) Peptide deformylase inhibitors
MA21030A1 (en) BENZHYDRYLOXYETHYL-PIPERAZINE DERIVATIVES AND PROCESS FOR OBTAINING THE SAME.
NZ331646A (en) Aryloxy- and arylthio-substituted pyrimidines and triazines and derivatives thereof
US20060293297A1 (en) Cyanofluoropyrrolidine derviative
SI9720045B (en) Azolo triazines and pyrimidines
ATE113271T1 (en) HALOGEN-SUBSTITUTED AMINOTETRALINES.
NO874872L (en) CONDENSED HETEROCYCLIC TETRAHYDROAMINOQINOLINOLS AND RELATED COMPOUNDS AND PROCEDURES FOR PREPARING THEREOF.
TW200524880A (en) Pyrimidine compounds